Members of CAMP PCI’s faculty take questions from physician participants during the first virtual training on 5 June 2020, broadcast live from Abiomed’s Heart Recovery Institute Abiomed has launched a virtual physician education programme, CAMP PCI (Coronary artery and myocardial protected percutaneous coronary intervention), to improve high-risk PCI patient outcomes. A press [...]
Abiomed (maker of the Impella heart pump) has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. A press release reports that the acquisition will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation. Such patients include those with cardiogenic [...]
Abiomed’s Impella 5.5 with SmartAssist has received US FDA pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. The Impella 5.5 with SmartAssist system is a temporary ventricular support device intended for short term (14 days) use and indicated for the treatment of ongoing cardiogenic [...]
Carsten Tschöpe At the 2019 European Society of Cardiology (ESC) Congress (31 August–4 September, Paris, France), Carsten Tschöpe (Charité Hospital, Berlin, Germany) outlined the use of the “Propella” approach in myocarditis patients with cardiogenic shock. He explained that the approach involves the prolonged use of an Impella heart pump (Abiomed) to provide [...]